Abstract
Purpose: Age has been linked to outcome in renal cancer patients, but mainly in North American cohorts. In this study, we hypothesized that age is correlated with metastasis and cancer-specific survival in a German cohort regardless of types of treatments. Methods: A total of 1,538 patients treated for renal malignancies between 1991 and 2010 were evaluated. Mean age and median age are 61.9 ± 11.6 and 62.6 years. Clinicopathologic [tumor type, size, grade, stage and treatment (surgery, chemotherapy, radiation, immunotherapy)] and outcome parameters (metastasis and survival) were examined for an association with age using logistic regression and Cox proportional hazard model, and Kaplan-Meier plots. Results: Age was associated with stage, metastasis, treatment, cancer-specific and overall mortality (p < 0.01). The metastasis-free and cancer-free survival rates for patients >63 years were lower than those for patients ≤63 years (p < 0.0001). In a multivariate analysis, age was an independent prognostic factor of metastasis, cancer-specific and overall mortality (p < 0.0001) even when data were stratified in different decades and treatment was included as one of the parameters. Patients >63 years of age had 29-35 % higher risk of metastasis and cancer-specific mortality than younger patients. Median metastasis-free and cancer-specific survival for patients >63 years of age (months: 84.4; 70.3) was ~50 % shorter than in patients ≤63 years (months: 151; 144.6). Conclusions: This large study shows that, despite advances in surgical and non-surgical treatment modalities over the two decades, age is an independent prognostic indicator of metastasis and cancer-specific mortality in renal cancer patients. Patients >63 years have ~30 % increased risk for metastasis and ~50 % shorter cancer-specific survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 115-121 |
| Number of pages | 7 |
| Journal | World Journal of Urology |
| Volume | 32 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 1 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- Age
- Cancer-specific survival
- Metastasis
- Prognostic indicators
- Renal malignancies
- Treatment
ASJC Scopus subject areas
- Urology
Cite this
Age-an independent prognostic factor of clinical outcome in renal malignancies : Results of a large study over two decades. / Hupe, Marie C.; Merseburger, Axel S.; Lokeshwar, Vinata B.; Eggers, Hendrik; Rott, Hendrik; Wegener, Gerd; Abbas, Mahmoud; Kuczyk, Markus A.; Herrmann, Thomas R.
In: World Journal of Urology, Vol. 32, No. 1, 01.02.2014, p. 115-121.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Age-an independent prognostic factor of clinical outcome in renal malignancies
T2 - Results of a large study over two decades
AU - Hupe, Marie C.
AU - Merseburger, Axel S.
AU - Lokeshwar, Vinata B.
AU - Eggers, Hendrik
AU - Rott, Hendrik
AU - Wegener, Gerd
AU - Abbas, Mahmoud
AU - Kuczyk, Markus A.
AU - Herrmann, Thomas R.
PY - 2014/2/1
Y1 - 2014/2/1
N2 - Purpose: Age has been linked to outcome in renal cancer patients, but mainly in North American cohorts. In this study, we hypothesized that age is correlated with metastasis and cancer-specific survival in a German cohort regardless of types of treatments. Methods: A total of 1,538 patients treated for renal malignancies between 1991 and 2010 were evaluated. Mean age and median age are 61.9 ± 11.6 and 62.6 years. Clinicopathologic [tumor type, size, grade, stage and treatment (surgery, chemotherapy, radiation, immunotherapy)] and outcome parameters (metastasis and survival) were examined for an association with age using logistic regression and Cox proportional hazard model, and Kaplan-Meier plots. Results: Age was associated with stage, metastasis, treatment, cancer-specific and overall mortality (p < 0.01). The metastasis-free and cancer-free survival rates for patients >63 years were lower than those for patients ≤63 years (p < 0.0001). In a multivariate analysis, age was an independent prognostic factor of metastasis, cancer-specific and overall mortality (p < 0.0001) even when data were stratified in different decades and treatment was included as one of the parameters. Patients >63 years of age had 29-35 % higher risk of metastasis and cancer-specific mortality than younger patients. Median metastasis-free and cancer-specific survival for patients >63 years of age (months: 84.4; 70.3) was ~50 % shorter than in patients ≤63 years (months: 151; 144.6). Conclusions: This large study shows that, despite advances in surgical and non-surgical treatment modalities over the two decades, age is an independent prognostic indicator of metastasis and cancer-specific mortality in renal cancer patients. Patients >63 years have ~30 % increased risk for metastasis and ~50 % shorter cancer-specific survival.
AB - Purpose: Age has been linked to outcome in renal cancer patients, but mainly in North American cohorts. In this study, we hypothesized that age is correlated with metastasis and cancer-specific survival in a German cohort regardless of types of treatments. Methods: A total of 1,538 patients treated for renal malignancies between 1991 and 2010 were evaluated. Mean age and median age are 61.9 ± 11.6 and 62.6 years. Clinicopathologic [tumor type, size, grade, stage and treatment (surgery, chemotherapy, radiation, immunotherapy)] and outcome parameters (metastasis and survival) were examined for an association with age using logistic regression and Cox proportional hazard model, and Kaplan-Meier plots. Results: Age was associated with stage, metastasis, treatment, cancer-specific and overall mortality (p < 0.01). The metastasis-free and cancer-free survival rates for patients >63 years were lower than those for patients ≤63 years (p < 0.0001). In a multivariate analysis, age was an independent prognostic factor of metastasis, cancer-specific and overall mortality (p < 0.0001) even when data were stratified in different decades and treatment was included as one of the parameters. Patients >63 years of age had 29-35 % higher risk of metastasis and cancer-specific mortality than younger patients. Median metastasis-free and cancer-specific survival for patients >63 years of age (months: 84.4; 70.3) was ~50 % shorter than in patients ≤63 years (months: 151; 144.6). Conclusions: This large study shows that, despite advances in surgical and non-surgical treatment modalities over the two decades, age is an independent prognostic indicator of metastasis and cancer-specific mortality in renal cancer patients. Patients >63 years have ~30 % increased risk for metastasis and ~50 % shorter cancer-specific survival.
KW - Age
KW - Cancer-specific survival
KW - Metastasis
KW - Prognostic indicators
KW - Renal malignancies
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84893141725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893141725&partnerID=8YFLogxK
U2 - 10.1007/s00345-013-1164-6
DO - 10.1007/s00345-013-1164-6
M3 - Article
C2 - 24085371
AN - SCOPUS:84893141725
VL - 32
SP - 115
EP - 121
JO - World Journal of Urology
JF - World Journal of Urology
SN - 0724-4983
IS - 1
ER -